Merck, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: $295.3B

Website: http://www.merck.ph

Clinical Trials

Treatment of Sarcopenia in Post-Hip Fracture Patients (0677-032)

Phase 2

Terminated

Conditions: Hip Fracture

First Posted Date: 2005-08-09

Last Posted Date: 2016-01-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 83

Registration Number: NCT00128115

Locations: 🇳🇴
MSD (Norge) AS, Drammen, Norway
🇸🇪
Merck Sharp & Dohme (Sweden) AB, Sollentuna, Sweden
🇩🇪
Msd Sharp & Dohme Gmbh, Haar, Germany

and more 2 locations

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014)

Phase 3

Completed

Conditions: Mesothelioma
Lung Cancer

Interventions: Drug: Placebo
Drug: Vorinostat

First Posted Date: 2005-08-09

Last Posted Date: 2020-10-26

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 661

Registration Number: NCT00128102

A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030)

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2015-09-28

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 10

Registration Number: NCT00127140

An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2015-04-21

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 23

Registration Number: NCT00127101

A Study of an Investigational Drug Sitagliptin for Type 2 Diabetes Mellitus (0431-044)

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: sitagliptin phosphate

First Posted Date: 2005-08-05

Last Posted Date: 2015-06-15

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 363

Registration Number: NCT00127192

A Study of V110 a Pneumococcal Vaccine in Healthy Adults (V110-013)

Phase 3

Completed

Conditions: Healthy
Pneumococcal Infections

First Posted Date: 2005-08-05

Last Posted Date: 2015-01-29

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 130

Registration Number: NCT00127153

A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)

Phase 1

Completed

Conditions: Tumors

Interventions: Drug: vorinostat

First Posted Date: 2005-08-05

Last Posted Date: 2022-09-13

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 18

Registration Number: NCT00127127

A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)

Phase 2

Terminated

Conditions: Non-small-cell Lung Carcinoma
Breast Cancer
Colorectal Cancer

First Posted Date: 2005-08-04

Last Posted Date: 2017-04-10

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 16

Registration Number: NCT00126451

A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)

Phase 3

Completed

Conditions: Anesthesia

Interventions: Drug: rocuronium continuous infusion maintenance
Drug: Rocuronium bolus maintenance

First Posted Date: 2005-07-28

Last Posted Date: 2016-08-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 149

Registration Number: NCT00124735

A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia

Phase 3

Completed

Conditions: Anesthesia

Interventions: Drug: Rocuronium bromide (Zemuron)

First Posted Date: 2005-07-28

Last Posted Date: 2015-06-01

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 207

Registration Number: NCT00124722

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy